Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400235 | 0.87 | ALDH1A1 (0.59) | ALDH1A1KMT2AMAPTNPC1MEN1 | |
| SCHEMBL13990244 | 0.80 | TSHR (0.53) | ALDH1A1KMT2AMAPTNPC1MEN1 | |
| SCHEMBL16924614 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KMT2AMAPTNPC1MEN1 | |
| SCHEMBL6731238 | 0.79 | ALDH1A1 (0.52) | ALDH1A1KMT2AMAPTNPC1MEN1 | |
| SCHEMBL16316318 | 0.79 | ALDH1A1 (0.49) | ALDH1A1KMT2AMAPTNPC1MEN1 | |
| SCHEMBL14112770 | 0.79 | ALDH1A1 (0.49) | ALDH1A1KMT2AMAPTNPC1MEN1 | |
| SCHEMBL22171703 | 0.78 | KMT2A (0.54) | ALDH1A1KMT2AMAPTMEN1L3MBTL1 | |
| SCHEMBL9476229 | 0.78 | SLC9A1 (0.65) | ALDH1A1KMT2AMAPTNPC1MEN1 | |
| SCHEMBL2322204 | 0.77 | KMT2A (0.61) | ALDH1A1KMT2AMAPTNPC1MEN1 | |
| SCHEMBL2322196 | 0.77 | ALDH1A1 (0.50) | ALDH1A1KMT2AMAPTNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | SMITH CHARLES D (US) | 2004-01-22 | — | — | US | claimed |
| US-10287283-B2 | Read-through compound prodrugs suppressing premature nonsense mutations | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190084973-A1 | READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-03-21 | — | — | US | disclosed |
| US-20160333003-A1 | READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-17 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-20120010259-A1 | Methods of Treating an Overweight or Obese Subject | ZAFGEN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7238688-B2 | Piperidine compounds | SCHERING CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | SMITH CHARLES D (US) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | ALDH1A1 2674/4885KMT2A 2604/4885MAPT 4160/4885 |
| US-20120010259-A1 | Methods of Treating an Overweight or Obese Subject | METAP2, METAP1, ACER2 | ALDH1A1 802/4885KMT2A 444/4885MAPT 3100/4885 |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | GABRA5, GABRA4, GABRA3 | ALDH1A1 372/4885KMT2A 1440/4885MAPT 1578/4885 |
| US-20190084973-A1 | READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS | UPF1, NUDT21, RNMT | ALDH1A1 3413/4885KMT2A 1096/4885MAPT 269/4885 |
| US-20160333003-A1 | READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS | UPF1, NUDT21, RNMT | ALDH1A1 3413/4885KMT2A 1096/4885MAPT 269/4885 |
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | NMT2, NMT1, MBOAT1 | ALDH1A1 4793/4885KMT2A 440/4885MAPT 133/4885 |
| US-10287283-B2 | Read-through compound prodrugs suppressing premature nonsense mutations | UPF1, NUDT21, RNMT | ALDH1A1 3413/4885KMT2A 1096/4885MAPT 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.